- Home
- MMC vs SNY Comparison
MMC vs SNY Comparison
Compare MMC & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MMC
- SNY
- Stock Information
- Founded
- MMC 1871
- SNY 1994
- Country
- MMC United States
- SNY France
- Employees
- MMC N/A
- SNY N/A
- Industry
- MMC Specialty Insurers
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- MMC Finance
- SNY Health Care
- Exchange
- MMC Nasdaq
- SNY Nasdaq
- Market Cap
- MMC 103.4B
- SNY 113.4B
- IPO Year
- MMC N/A
- SNY N/A
- Fundamental
- Price
- MMC $202.93
- SNY $47.03
- Analyst Decision
- MMC Hold
- SNY Buy
- Analyst Count
- MMC 14
- SNY 4
- Target Price
- MMC $235.86
- SNY $61.50
- AVG Volume (30 Days)
- MMC 2.0M
- SNY 2.8M
- Earning Date
- MMC 10-16-2025
- SNY 10-24-2025
- Dividend Yield
- MMC 1.77%
- SNY 3.40%
- EPS Growth
- MMC 3.35
- SNY 118.56
- EPS
- MMC 8.33
- SNY 8.65
- Revenue
- MMC $25,799,000,000.00
- SNY $53,714,621,258.00
- Revenue This Year
- MMC $11.57
- SNY $2.01
- Revenue Next Year
- MMC $5.57
- SNY $6.82
- P/E Ratio
- MMC $24.37
- SNY $10.74
- Revenue Growth
- MMC 9.18
- SNY 15.65
- 52 Week Low
- MMC $196.27
- SNY $44.73
- 52 Week High
- MMC $248.00
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- MMC 43.37
- SNY 42.55
- Support Level
- MMC $198.06
- SNY $46.79
- Resistance Level
- MMC $207.08
- SNY $47.69
- Average True Range (ATR)
- MMC 2.97
- SNY 0.71
- MACD
- MMC -0.35
- SNY -0.27
- Stochastic Oscillator
- MMC 36.84
- SNY 32.62
About MMC Marsh & McLennan Companies Inc.
Marsh McLennan is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (a management and economic consultancy). About half of its revenue is generated outside the US.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.